Ken, this is a good opportunity to consolidate several

New Post Public Reply Private Reply Replies (1) Message Board
MGK_2 KenChowder #163090
531
Ken, this is a good opportunity to consolidate several threads into one clean reply, so let me do that.
On the AI tinge: the observation is noted. The analytical framework stands on peer-reviewed citations that can be verified independently of whoever compiled them. The conjecture label on forward-looking projections is fair and accepted. What can be documented is documented. What is projected is projected. The two have been kept deliberately separate throughout, though the line between them is not always as clean as it should be.

On credentials: your argument is well-constructed and accepted rather than deflected. Credentials help a reader calibrate the weight of a conjecture, and you are right that the current information environment makes that calibration harder without them. The response to that problem is to keep the analysis anchored to sources the reader can verify independently. Whether that fully resolves the problem you raise is uncertain.

On the ESMO abstract category observation: this is a useful thing. A small correction on the timeline: the ESMO outcome notifications to submitters are expected between July 8 and 10, not July 17. The July 17 date is when accepted abstract titles appear publicly in the program section. Dr. Kasi's team at City of Hope will know the presentation tier approximately one week before the community sees the title. Presidential Symposium means clinical practice-changing. Proffered Paper means original data of superior quality. Rapid Oral means good quality. Poster means acceptable but not oral-worthy. 

The ASCO situation is the correct baseline: the CLOVER abstract received no formal presentation slot in January 2026, only an abstract publication. The data available for the ESMO Madrid submission is substantially more mature. The tier assigned between July 8 and 10 will be the first external signal of how the ESMO Scientific Committee weighted it, before a single result number is publicly disclosed. You identified a genuine leading indicator.

Now to Jake's friend, relayed through you via the dunce section of the classroom, which continues to ask better questions than most of the honor roll.

Does size count? Yes, and the published data supports it with more precision than the question implies.

The seven-year HIV leronlimab study published in PLOS Pathogens confirms that both 350mg and 700mg achieved full CCR5 receptor occupancy on peripheral blood CD4+ T cells and monocytes in human participants. In peripheral blood, 350mg is not a subtherapeutic dose. It fully saturates the receptors it can reach in circulation.
The problem is not the blood. It is the liver.

The liver in a colorectal cancer patient with hepatic metastases contains an enormous reservoir of CCR5-bearing cells: Kupffer cells, hepatic stellate cells, recruited monocyte-derived macrophages, CAMLs, tumor-infiltrating myeloid cells, and the CCR5-positive tumor cells themselves in the metastatic lesions. This is the liver sink, and its size is directly proportional to the patient's body mass, liver volume, and metastatic tumor burden. A smaller patient with lower body weight, smaller liver volume, and lower metastatic burden has a proportionally smaller liver sink. The 350mg dose achieves functional CCR5 saturation of that smaller sink more completely than it does in a larger patient whose hepatic CCR5 burden is proportionally greater.

The JCO pooled mTNBC analysis confirms the dose-response signal in oncology specifically: patients treated with 525 to 700mg doses had greater than 75 percent improved median PFS compared to patients at lower doses. That improvement is not simply a pharmacokinetic artifact of larger patients needing more drug. It reflects the biological reality that deeper and more sustained CCR5 saturation in the hepatic and tumor compartments produces more durable immune architecture conversion and more sustained chemotherapy sensitization.

Now add the CCR5 clustering and endocytosis mechanism confirmed in the AACR B019 abstract, where higher leronlimab doses were specifically associated with the formation of CCR5 dots in CAMLs and CTCs. The clustering mechanism means each leronlimab binding event triggers a cascade that removes multiple receptors from the cell surface simultaneously through clathrin-mediated endocytosis, achieving higher functional receptor occupancy than the dose-to-receptor ratio calculation alone suggests. In a smaller patient where the 350mg dose is already approaching saturation of the total receptor burden, the clustering mechanism pushes functional saturation beyond what the arithmetic predicts. In a larger patient with a greater hepatic CCR5 burden, the 700mg dose is required to initiate enough clustering events to achieve the same functional coverage.

This is likely why three of the four complete ctDNA clearances in CLOVER came from the 350mg cohort. Those three patients were probably smaller in body size and lower in hepatic metastatic burden, meaning 350mg achieved functional receptor saturation in their specific liver sink through the clustering mechanism. The fourth complete clearance, from the 700mg cohort, came from a patient whose receptor burden required the higher dose to achieve the same functional saturation.

Jake's friend found a real variable. It is not the whole story, but it is a genuine and published piece of the receptor occupancy architecture. 

Size, liver metastatic burden, and the clustering-induced functional saturation mechanism all operate simultaneously, and together they explain why the dose-response question in CLOVER is more nuanced than a simple 350mg versus 700mg comparison implies.

The dunce section keeps finding the right questions. The honor roll potentially could learn something.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 106

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 58

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
Millrose Lawsuit Puts Disclosure Discipline in Focus

Updated Category News Views 64

A supposedly clean homesite-option story has wandered into the legal weeds, and that is exactly where investors need to slow down. A shareholder class action against Millrose Properties alleges the company painted one business model for the market while pursuing a materially different one behind the curtain. That allegation has not been proven in court, and anybody...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 103

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 93

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 28

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 93

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 58

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading

Top 5 Most Recently Viewed Articles

AI/R Targets 2025 IPO Amidst Rapid AI Advancements

Updated Category News Views 488

AI/R Sets 2025 IPO Goals as AI Innovations Surge AI/R, a leading provider of artificial intelligence platforms and services, has exciting plans for a public offering in 2025. As a global player in the AI industry, renowned companies like Toyota, BP, and Nestlé benefit from AI/R's innovative solutions. The company anticipates impressive revenues exceeding $350 million for...

Continue Reading
Sable Implements New Equity Plan to Enhance Shareholder Value

Updated Category News Views 228

Sable Resources Ltd. Unveils Innovative Equity Incentive Plan VANCOUVER, British Columbia — Sable Resources Ltd. (“Sable” or the “Company”) (TSXV: SAE | OTCQB: SBLRF) has announced an exciting new chapter for the company with the recent approval of its Equity Incentive Plan at the annual shareholder meeting. The approval reflects strong support from...

Continue Reading
Unlock Savings This Black Friday with AKKO's Amazing Deals

Updated Category News Views 163

Get Ready for AKKO's Black Friday Extravaganza As the holiday season draws near, AKKO is set to surprise European users with spectacular Black Friday deals. During this promotional event, you can enjoy discounts of up to 50% on premium mechanical keyboards, keycaps, and various accessories. Whether you are a competitive gamer seeking high performance or an everyday user...

Continue Reading
Ping An Health Sets Benchmark with WONCA Certifications in Care

Updated Category News Views 156

Ping An Health Achieves Notable WONCA Certifications Recently, Ping An Healthcare Technology Co., Ltd. successfully obtained the prestigious Digital Health Certificate (DHC) and the Development & Enhancement Program (DEP) Certificate from the World Organization of Family Doctors (WONCA). This makes Ping An Health the first healthcare and eldercare service company in the...

Continue Reading
Gallatin AI's Navigator Solution Gains DoD Recognition

Updated Category News Views 277

Gallatin AI's Navigator Solution Gains 'Awardable' Status Gallatin AI, an innovative startup committed to evolving defense logistics, has announced significant news regarding its flagship product, Gallatin Navigator. This advanced logistics operating system has officially achieved 'Awardable' status under the Department of Defense's Tradewinds Solutions Marketplace. This...

Continue Reading